Answers are grounded in this paper and cite their sources.
Preclinical evaluation of hetrombopag demonstrates enhanced efficacy in promoting cell viability and growth in thrombocytopenia models, indicating potential clinical benefits.
Nonpeptide thrombopoietin receptor ( TPOR / MPL ) agonists, such as eltrombopag, have been used to treat thrombocytopenia of various aetiologies. Here, we investigated the pharmacological properties of hetrombopag, a new orally active small‐molecule TPOR agonist, in preclinical models. Hetrombopag specifically stimulated proliferation and/or differentiation of human TPOR ‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells, with low nanomolar EC 50 values through stimulation of STAT , PI 3K and ERK signalling pathways. Notably, hetrombopag effectively up‐regulated G 1 ‐phase–related proteins, including p‐ RB , Cyclin D1 and CDK 4/6, normalized progression of the cell cycle, and prevented apoptosis by modulating BCL ‐ XL / BAK expression in 32D‐ MPL cells. Moreover, hetrombopag and TPO acted additively in stimulating TPOR ‐dependent signalling, promoting cell viability, and preventing apoptosis. Orally administered hetrombopag specifically promoted the viability and growth of 32D‐ MPL cells in hollow fibres implanted into nude mice with much higher potency than that of the well‐known TPOR agonist, eltrombopag, in association with activation of TPOR ‐dependent signal transduction in vivo. Taken together, our findings indicate that, given its favourable pharmacological characteristics, hetrombopag may represent a new, orally active, small‐molecule TPOR agonist for patients with thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: